Urinary System Adenocarcinoma — Trials

Urinary System Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 378
Recruiting: 195
Ph III recruiting: 14
Growth YoY: +1.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (279)

clinicaltrialsPublishedShowing 251–273 of 273 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00267748	Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)	completed	Phase 2	317	PfizerINDUSTRY	1	Sep 5, 2011	clinicaltrials
NCT00113529	Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma	completed	Phase 1 / Phase 2	42	PfizerINDUSTRY	1	Aug 29, 2011	clinicaltrials